spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Loxo Oncology 

 HSMN NewsFeed - 20 Aug 2025
Anne White to Retire as Executive Vice President and President, Lilly Neuroscience
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 13 Dec 2021
Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control(R) Platform
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Oct 2021
FDA Approves Verzenio(R) (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Aug 2021
Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Jan 2021
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Sep 2019
Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Aug 2019
Lilly Announces Leadership Changes in Corporate Business Development, Oncology R&D, and Managed Healthcare Services
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Feb 2019
Lilly Completes Acquisition of Loxo Oncology
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 18 Jan 2019
Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jan 2019
Lilly Announces Agreement To Acquire Loxo Oncology
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 7 Aug 2018
Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI(TM) in combination with MEKTOVI(R) and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Jul 2018
The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI(TM) (encorafenib) in Combination with MEKTOVI(R) (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Mar 2018
Bayer Announces Completion of Rolling Submission of New Drug Application in the U.S. for Larotrectinib for the Treatment of TRK Fusion Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 31 May 2017
Array BioPharma And Ono Pharmaceutical Co., Ltd. Announce A License, Development And Commercialization Partnership For Two Novel Oncology Compounds, Binimetinib And Encorafenib
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jan 2017
Verastem Announces Executive Leadership Appointments and Changes
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Sep 2015
Lori Kunkel, M.D., Joins Tocagen's Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Oct 2013
Loxo Oncology Raises $33 Million in Series A Financing to Fund Development of Small Molecule Oncology Drugs
Biopharmaceuticals Oncology Venture Capital
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.